| Trial | Title | Study Record Detail | Phase | Sponsor/Collaborator |
|---|---|---|---|---|
| A Study Of PF-06263507 In Patients With Advanced Solid Tumors | NCT01891669 | Phase I | Oxford BioMedica/Pfizer (Wyeth) |
Last Editorial Review:July 7, 2015
Home PF 06263507 (A1-mcMMAF / Anti-5T4 monoclonal antibody – Pfizer / PF-06263507) Clinical Trials
